Chicago Partners Investment Group LLC Has $669,000 Position in Ascendis Pharma A/S (NASDAQ:ASND)

Chicago Partners Investment Group LLC decreased its position in shares of Ascendis Pharma A/S (NASDAQ:ASNDGet Rating) by 15.8% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,781 shares of the biotechnology company’s stock after selling 1,465 shares during the quarter. Chicago Partners Investment Group LLC’s holdings in Ascendis Pharma A/S were worth $669,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SG Americas Securities LLC boosted its stake in Ascendis Pharma A/S by 17.8% during the 1st quarter. SG Americas Securities LLC now owns 942 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 142 shares during the last quarter. Captrust Financial Advisors grew its holdings in shares of Ascendis Pharma A/S by 3,069.7% in the 1st quarter. Captrust Financial Advisors now owns 1,046 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 1,013 shares in the last quarter. Icapital Wealth LLC bought a new stake in Ascendis Pharma A/S during the first quarter worth $166,000. Guggenheim Capital LLC grew its holdings in Ascendis Pharma A/S by 7.2% during the first quarter. Guggenheim Capital LLC now owns 2,008 shares of the biotechnology company’s stock worth $236,000 after purchasing an additional 135 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new position in shares of Ascendis Pharma A/S during the 1st quarter worth approximately $237,000.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on ASND shares. SVB Leerink dropped their price objective on shares of Ascendis Pharma A/S from $174.00 to $168.00 and set an “outperform” rating for the company in a research note on Thursday, August 11th. Berenberg Bank reiterated a “buy” rating and issued a $166.00 target price on shares of Ascendis Pharma A/S in a research report on Tuesday, August 30th. Morgan Stanley decreased their price target on shares of Ascendis Pharma A/S from $152.00 to $148.00 and set an “overweight” rating on the stock in a report on Thursday, August 11th. Finally, Oppenheimer reduced their price objective on Ascendis Pharma A/S from $154.00 to $144.00 and set an “outperform” rating on the stock in a research report on Thursday, August 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $154.10.

Ascendis Pharma A/S Price Performance

ASND stock opened at $106.61 on Thursday. Ascendis Pharma A/S has a 1 year low of $61.58 and a 1 year high of $172.65. The stock has a market capitalization of $6.07 billion, a PE ratio of -13.51 and a beta of 0.66. The company’s 50-day moving average is $92.62 and its 200-day moving average is $96.70. The company has a debt-to-equity ratio of 0.82, a current ratio of 9.66 and a quick ratio of 8.78.

Ascendis Pharma A/S (NASDAQ:ASNDGet Rating) last announced its quarterly earnings data on Wednesday, August 10th. The biotechnology company reported ($1.54) EPS for the quarter, beating analysts’ consensus estimates of ($2.11) by $0.57. Ascendis Pharma A/S had a negative return on equity of 48.92% and a negative net margin of 2,099.51%. The firm had revenue of $6.51 million during the quarter, compared to analysts’ expectations of $7.07 million. Equities research analysts expect that Ascendis Pharma A/S will post -8.77 EPS for the current fiscal year.

Ascendis Pharma A/S Company Profile

(Get Rating)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.

Further Reading

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASNDGet Rating).

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.